EP0536245A1 - Novel, protracted insulin analogues - Google Patents

Novel, protracted insulin analogues

Info

Publication number
EP0536245A1
EP0536245A1 EP91912264A EP91912264A EP0536245A1 EP 0536245 A1 EP0536245 A1 EP 0536245A1 EP 91912264 A EP91912264 A EP 91912264A EP 91912264 A EP91912264 A EP 91912264A EP 0536245 A1 EP0536245 A1 EP 0536245A1
Authority
EP
European Patent Office
Prior art keywords
arg
lys
pro
human insulin
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91912264A
Other languages
German (de)
French (fr)
Inventor
Jan Markussen
Liselotte Langkjaer
Kjeld Norris
Leo Boye Snel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0536245A1 publication Critical patent/EP0536245A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel insulin analogues with a prolonged insulin action, to a process for the preparation of such insulin analogues and to injectable solutions containing the novel insulin analogues.
  • Insulin analogues with a protracted insulin action have previously been described in EP 0194864A and EP 0254516A.
  • EP 0194864A protracted human insulin analogues wherein the C-terminal carboxyl group of the B-chain is blocked with an amido or ester residue and the amino acid residue in position A4, A17, B13 and B21 may be substituted by Gin are described.
  • EP 0254516A describes human insulin of the same type as in EP 0194486A but further being modified in the A21 position.
  • Some of the above insulin analogues may, however, show a too low biological potency or the level of prolongation may be too low for specific purposes.
  • the present invention is thus related to novel analogues of human insulin wherein at least one of the amino acid residues from B1 to B6 has been replaced by a basic amino acid residue, i.e. a lysine or arginine residue (Lys or Arg).
  • a basic amino acid residue i.e. a lysine or arginine residue (Lys or Arg).
  • asparagine (Asn) in position A21 may furthermore be substituted with another amino acid residue.
  • a further positive charge may be introduced by blocking the C-terminal carboxyl group in position B30 preferably by means of an amido or ester group.
  • the amino group linked to the C-terminal end of the Lys or Arg residue substituent is a proline residue.
  • the invention is also related to a method for the preparation of the novel insulin analogues by which a biosynthetic precursor of the insulin analogue is converted into the insulin analogues by enzymatic and chemical conversion and to insulin solutions containing the novel insulin analogues.
  • insulin analogues as used herein is meant a compound having a molecular structure similar to that of insulin including the disulphide bridges between Cys A7 and Cys B7 , and between Cys A20 and Cys B19 and an internal disulphide bridge between Cys A6 and Cys A11 and with insulin activity.
  • the present insulin analogues may be represented by the following formula I
  • Z is Asn or another naturally occuring amino acid residue
  • X 1 is Phe, Lys or Arg
  • X 2 is Val, Lys or Arg
  • X 3 is Asn, Lys, Arg or Pro
  • X 4 is Gin, Lys, Arg or Pro
  • X 5 is His, Lys, Arg or Pro
  • X 6 is Lys, Arg, Leu or Pro
  • Y is a threonine residue wherein the carboxyl group may be blocked by an ester or amido group, with the proviso that at least one of X 1 , X 2 , X 3 , X 4 , X 5 and X 6 is Lys or Arg.
  • the change in charge is obtained by substituting one or more of the amino acid residues in position B1 to B6 with an arginine or lysine residue.
  • the C-terminal carboxyl group of the B- chain may be blocked by an ester group or amide group.
  • Z is not asparagine it may be a neutral amino acid, for example valine, glutamine, isoleucine, leucine, phenylalanine, tyrosine, methionine or preferably glycine, serine, threonine or alanine.
  • Z may also be an acidic amino acid, viz. glutamic acid or aspartic acid, or a basic amino acid, viz. lysine, arginine or histidine.
  • Z is preferably glycine, alanine or serine.
  • blocking groups of the C-terminal carboxyl group in the B30 amino acid residue (threonine) are ester moities such as lower alkoxy with preferably not more than 8 carbon atoms, preferably less than 5 carbon atoms.
  • Preferred alkoxy groups are methoxy, ethoxy and tertiary butoxy.
  • the blocking group may also be an amido group with the formula -NR 1 R 2 wherein R 1 and R 2 are the same or different and each represents hydrogen or alkyl with preferably up to 8 carbon atoms. R 1 and R 2 are preferably each hydrogen.
  • the degree of prolongation can be enhanced and controlled by the addition of zinc ions.
  • Parameters that may control the degree of prolongation of the insulin effect are the concentration of zinc and the choice of the compound of formula I.
  • the range for preferred zinc content extends from 0 to about 2 mg/ml, preferably from 0 to 200 ⁇ g/ml zinc and more preferably from about 20 to 200 ⁇ g/ml in a preparation containing about 240 nmole of a compound of formula I per ml. Using other concentrations of the compound of formula I, the content of zinc is to be adjusted correspondingly.
  • the pH of the injectable solution of this invention should preferably be below the physiological pH, the upper limit being the pH where precipitation occurs. At the physiological pH value, compounds of formula I of this invention have a low solubility. Stable solutions containing about 240 nmole/ml of compounds of formula I per ml have been obtained at pH about 5.5. The upper limit depends upon the constituents of the solution, i.e. isotonikum, preservative and zinc concentration, and upon the choice of compound of formula I. There is no lower pH limit of the solutions and the chemical stability of the compounds of formula I where Z is different from asparagine, is high, even at pH 3.
  • the preferred pH range for the injectable solutions of this invention is from about 2.5 to 8.5, more preferred from about 4.5 to 8. Especially preferred are pH ranges about 2.5 to 5.5, most prefered about 3 to 4.5.
  • a furter aspect of this invention is that it provides improved flexibility for the patients.
  • the patient With two aqueous solutions, one containing a compound of formula I and the other containing a zinc salt, the patient can obtain a desired degree of prolonged action and a desired profile by mixing the two solutions appropriately.
  • the patient has, using two stock solutions, the possibility of choosing one action and profile for the morning injection and another action and profile for the evening injection.
  • the zinc solution of this invention contains between about 2 ⁇ g and 20 mg zinc per ml.
  • both of the stock solutions may contain zinc, either in the same or different concentrations, and/or both the stock solutions may contain a compound of formula I, either the same or different compounds.
  • the injectable solutions of this invention have a strength of between about 60 and 6000 nmole of the compound of formula I per ml.
  • novel insulin analogues according to the present invention may be prepared by altering the proinsulin gene through replacement of codon(s) at the appropriate site in the native human proinsulin gene by codon(s) encoding the desired amino acid residue substitute (s) or by synthesizing the whole DNA-sequence encoding the desired insulin analogue.
  • the gene encoding the desired insulin analogue is then inserted into a suitable expression vector which when transferred to a suitable host organism, e.g. E. coli, Bacillus or yeast, generates the desired product.
  • the expressed product is then isolated from the cells or the culture broth depending on whether the expressed product is secreted from the cells or not.
  • novel insulin analogues may also be prepared by chemical synthesis by methods analogue to the method described by Marki et al. (Hoppe-Seyler's Z. Physiol.Chem., 360 (1979), 1619-1632). They may also be formed from separately in vitro prepared A- and B-chains containing the appropriate amino acid residue substitutions, whereupon the modified A- and B-chains are linked together by establishing disulphide bridges according to known methods (e.g. Chance et al., In: Rick DH, Gross E (eds) Peptides: Synthesis - Structure - Function. Proceedings of the seventh American peptide symposium, Illinois, pp. 721-728).
  • the insulin analogues may furthermore be prepared by a method analogue to the method described in EP 0163529A, the disclosure of which is incorporated by reference hereinto.
  • a method analogue to the method described in EP 0163529A an insulin precursor of human insulin wherein LyS B29 is connected to Gly A1 by means of either a peptide bond or a peptide chain of varying length with correctly positioned disulphide bridges is expressed and secreted by yeast and then converted into human insulin by the so-called transpeptidation reaction.
  • transpeptidation reaction is described in US patent specification No. 4,343,898 (the disclosure of which is incorporated by reference hereinto).
  • this reaction the peptide bond or peptide chain connecting Lys B29 and Gly A1 is exised and a threonine ester or threonine amide group is coupled to the C-terminal end of Lys B29 .
  • novel insulin analogues may thus be prepared by a method wherein a biosynthetic insulin precursor with the following formula II
  • Q is a peptide chain with q amino acid residues, q is an interger from 0 to 33, T is Lys or Arg, r is 0 or 1 and X 1 , X 2 , X 3 , X 4 , X 5 , X 6 and Z are defined as above, is reacted with a compound of the formula III
  • HY (III) wherein Y is a protected threonine amino acid wherein the carboxyl group is protected with an ester or amido group, using trypsin or trypsin like enzymes as a catalyst in a mixture of water and organic solvent. The ester or amido protecting group may then be cleaved off by acid or basic hydrolysis.
  • Preferred compounds of formula III are Thr-NH 2 , Lys(Boc)-NH 2 , Thr(Bu t )-OBu t and Thr-OBu t .
  • Insulin preparations of this invention are prepared by dissolving a compound of formula I in an aqueous medium at slightly acidic conditions, for example, in a concentration of 240 or 600 nmole/ml.
  • the aqueous medium is made isotonic, for example, with sodium chloride or glycerol.
  • the aqueous medium may contain zinc ions in a concentraion of up to about 30 ⁇ g of Zn ++ per nmol of compound of formula I, buffers such as acetate, citrate and histidine and preservatives such as m-cresol, nipagin or phenol .
  • the pH value of the final insulin preparation depends upon the number of charges that have been changed in the compound of formula I, the concentration of zinc ions, the concentration of the compound of formula I and the compound of formula I selected.
  • the pH value is adjusted to a value convenient for administration such as about 2.5 - 5.5, preventing precipitation.
  • the insulin preparation is made sterile by sterile filtration.
  • the insulin preparations of this invention can be used similarly to the use of the known insulin preparations.
  • amino acids are those stated in J.Biol.Chem. 243 (1968), 3558.
  • the amino acids are in the L configuration. Unless otherwise indicated, the species of insulins stated herein is human.
  • B(l-29) means a shortened B-chain of human insulin from Phe B1 to LysB29 and A(1-21) means the A-chain of human insulin.
  • Arg B2 human insulin means a human insulin analogue wherein Arg has been substituted for Val in position 2 in the B-chain.
  • ArgB2 , B ( 1-29 )-Ala-Ala-Lys-A(1-21) human insulin means a precursor for the forementioned insulin analogue wherein Arg has been substituted for Val in position 2 in the shortened B-chain and wherein the B(1-29) chain and the A(1- 21) chain are connected by the peptide sequence Ala-Ala-Lys.
  • the B(l-29) chain and the A(1-21) chain are connected by disulphide bridges between Cys A7 and Cys B7 and between Cys A20 and Cys B19 , respectively, and that the A-chain contains an internal disulphide bridge between Cys A6 and Cys A1 , as in human insulin.
  • the insulin precursors were recovered from the fermentation broths by adsorption of LiChroprepTM RP-18 as described in Example 7 of EP 0163529A.
  • the precursors were eluted from the column with 0.2 M KCl, 0.001 M HCl in 33% (v/v) ethanol.
  • the insulin precursors were crystallized from the pool by successive additions of water (1 volume per volume of pool), solid trisodium citrate to obtain a molarity of 0.05 M and finally zinc acetate to obtain a molarity of 0.006 M.
  • the pH value was adjusted to 6.8 and the mixture was left overnight at 4°C.
  • the crystals were isolated by centrifugation, washed with water and dried in vacuo.
  • Sterile injectable solutions of the above compounds for testing of the degree of prolonged action were made using 1.6% (w/v) glycerol as the isotonicum, and 0.26% (w/v) phenol as the preservative.
  • the concentration of zinc ions was 8, 80 or 160 ⁇ g/ml.
  • the pH values of the solutions were adjusted sufficiently off the isoelectric point of the analogues to keep the solutions clear upon storage at 4°C.
  • the solutions contained 240 nmole/ml of the tested compounds. The concentration of 240 nmole/ml was verified by HPLC.

Abstract

Analogues d'insuline humaine à effet insulinique prolongé dans lesquels au moins l'un des restes d'acide aminé en position B1-B6 est remplacé par un reste de lysine (Lys) ou d'arginine (Arg). On peut remplacer Asn en position A21 par un autre reste d'acide aminé de façon à augmenter la statilité de l'anlogue insulinique dans une solution acide. De plus, on peut bloquer la position B30 à l'aide d'un groupe amido ou ester.Human insulin analogs with long-lasting insulin effect in which at least one of the amino acid residues at position B1-B6 is replaced by a residue of lysine (Lys) or arginine (Arg). Asn can be replaced in position A21 with another amino acid residue so as to increase the statility of the insulin-containing formulation in an acidic solution. In addition, the B30 position can be blocked using an amido or ester group.

Description

NOVEL, PROTRACTED INSULIN ANALOGUES
Field of invention
The present invention relates to novel insulin analogues with a prolonged insulin action, to a process for the preparation of such insulin analogues and to injectable solutions containing the novel insulin analogues.
Background of the invention
Insulin analogues with a protracted insulin action have previously been described in EP 0194864A and EP 0254516A.
In EP 0194864A protracted human insulin analogues wherein the C-terminal carboxyl group of the B-chain is blocked with an amido or ester residue and the amino acid residue in position A4, A17, B13 and B21 may be substituted by Gin are described. EP 0254516A describes human insulin of the same type as in EP 0194486A but further being modified in the A21 position.
Some of the above insulin analogues may, however, show a too low biological potency or the level of prolongation may be too low for specific purposes.
It is the purpose of the present invention to develop novel insulin analogues with prolonged insulin action not suffering from the above-mentioned drawbacks.
Summary of the invention
It has according to the present invention surprisingly been found that introduction of a positive charge in the N-terminal end of the B-chain gives rise to insulin analogues with a highly prolonged insulin action as compared to human insulin and also a high in vivo potency.
In its broadest aspect the present invention is thus related to novel analogues of human insulin wherein at least one of the amino acid residues from B1 to B6 has been replaced by a basic amino acid residue, i.e. a lysine or arginine residue (Lys or Arg).
For the purpose of improving the stability of the novel insulin analogues asparagine (Asn) in position A21 may furthermore be substituted with another amino acid residue.
Also a further positive charge may be introduced by blocking the C-terminal carboxyl group in position B30 preferably by means of an amido or ester group.
If the present insulin analogues are prepared by the socalled transpeptidition method (for details see later) it might furthermore be an advantage that the amino group linked to the C-terminal end of the Lys or Arg residue substituent is a proline residue.
The invention is also related to a method for the preparation of the novel insulin analogues by which a biosynthetic precursor of the insulin analogue is converted into the insulin analogues by enzymatic and chemical conversion and to insulin solutions containing the novel insulin analogues.
By "insulin analogues" as used herein is meant a compound having a molecular structure similar to that of insulin including the disulphide bridges between CysA7 and CysB7, and between CysA20 and CysB19 and an internal disulphide bridge between CysA6 and CysA11 and with insulin activity.
Detailed description of the invention
The present insulin analogues may be represented by the following formula I
wherein Z is Asn or another naturally occuring amino acid residue, X1 is Phe, Lys or Arg, X2 is Val, Lys or Arg, X3 is Asn, Lys, Arg or Pro, X4 is Gin, Lys, Arg or Pro, X5 is His, Lys, Arg or Pro, X6 is Lys, Arg, Leu or Pro and Y is a threonine residue wherein the carboxyl group may be blocked by an ester or amido group, with the proviso that at least one of X1 , X2, X3, X4, X5 and X6 is Lys or Arg.
Compared with human insulin, the change in charge is obtained by substituting one or more of the amino acid residues in position B1 to B6 with an arginine or lysine residue. In addition, the C-terminal carboxyl group of the B- chain may be blocked by an ester group or amide group.
If Z is not asparagine it may be a neutral amino acid, for example valine, glutamine, isoleucine, leucine, phenylalanine, tyrosine, methionine or preferably glycine, serine, threonine or alanine. Z may also be an acidic amino acid, viz. glutamic acid or aspartic acid, or a basic amino acid, viz. lysine, arginine or histidine. Z is preferably glycine, alanine or serine.
Examples of blocking groups of the C-terminal carboxyl group in the B30 amino acid residue (threonine) are ester moities such as lower alkoxy with preferably not more than 8 carbon atoms, preferably less than 5 carbon atoms. Preferred alkoxy groups are methoxy, ethoxy and tertiary butoxy.
The blocking group may also be an amido group with the formula -NR1R2 wherein R1 and R2 are the same or different and each represents hydrogen or alkyl with preferably up to 8 carbon atoms. R1 and R2 are preferably each hydrogen.
Since compounds of formula I can be applied in the clinic as solutions having a prolonged action, a decline in immunogenicity as compared to the commonly used suspensions of porcine or human insulins may occur.
The degree of prolongation can be enhanced and controlled by the addition of zinc ions.
Parameters that may control the degree of prolongation of the insulin effect are the concentration of zinc and the choice of the compound of formula I. The range for preferred zinc content extends from 0 to about 2 mg/ml, preferably from 0 to 200 μg/ml zinc and more preferably from about 20 to 200 μg/ml in a preparation containing about 240 nmole of a compound of formula I per ml. Using other concentrations of the compound of formula I, the content of zinc is to be adjusted correspondingly.
The prolonged action of solutions of compounds of formula I in the presence of zinc ions is ascribed to the low solubility of such compounds at neutral pH.
The pH of the injectable solution of this invention should preferably be below the physiological pH, the upper limit being the pH where precipitation occurs. At the physiological pH value, compounds of formula I of this invention have a low solubility. Stable solutions containing about 240 nmole/ml of compounds of formula I per ml have been obtained at pH about 5.5. The upper limit depends upon the constituents of the solution, i.e. isotonikum, preservative and zinc concentration, and upon the choice of compound of formula I. There is no lower pH limit of the solutions and the chemical stability of the compounds of formula I where Z is different from asparagine, is high, even at pH 3. The preferred pH range for the injectable solutions of this invention is from about 2.5 to 8.5, more preferred from about 4.5 to 8. Especially preferred are pH ranges about 2.5 to 5.5, most prefered about 3 to 4.5.
A furter aspect of this invention is that it provides improved flexibility for the patients. With two aqueous solutions, one containing a compound of formula I and the other containing a zinc salt, the patient can obtain a desired degree of prolonged action and a desired profile by mixing the two solutions appropriately. Thus, the patient has, using two stock solutions, the possibility of choosing one action and profile for the morning injection and another action and profile for the evening injection. Preferably, the zinc solution of this invention contains between about 2 μg and 20 mg zinc per ml. Alternatively, both of the stock solutions may contain zinc, either in the same or different concentrations, and/or both the stock solutions may contain a compound of formula I, either the same or different compounds.
Perferably, the injectable solutions of this invention have a strength of between about 60 and 6000 nmole of the compound of formula I per ml.
Examples of novel insulin analogues according to the present invention are
ArgB5,SerA21,ThrB30-NH2 human insulin
ArgB5,ProB6,SerA21,ThrB30-NH2 human insulin
ArgB5,GlyA21,ThrB30-NH2 human insulin
ArgB5,ProB6,GlyA21,ThrB30-NH2 human insulin
ArgB2,SerA21,ThrB30-NH2 human insulin
ArgB2,ProB3,SerA21,ThrB30-NH2 human insulin
ArgB2,GlyA21,ThrB30-NH2 human insulin
ArgB2,ProB3,GlyA21,ThrB30-NH2 human insulin
ArgB2,ArgB3,SerA21,ThrB30-NH2 human insulin
ArgB2,ArgB3,SerA21 human insulin
ArgB4,ProB5,SerA21,ThrB30-NH2 human insulin
ArgB4,ArgB5,ProB6,GlyA21,ThrB30 human insulin ArgB3,GlyA21,ThrB30-NH2 human insulin
ArgB3,SerA21,ThrB30-NH2 human insulin
ArgB4,GlyA21,ThrB30-NH2 human insulin
ArgB4,SerA21,ThrB30-NH2 human insulin
ArgB1,ProB2,GlyA21,ThrB30-NH2 human insulin.
The novel insulin analogues according to the present invention may be prepared by altering the proinsulin gene through replacement of codon(s) at the appropriate site in the native human proinsulin gene by codon(s) encoding the desired amino acid residue substitute (s) or by synthesizing the whole DNA-sequence encoding the desired insulin analogue. The gene encoding the desired insulin analogue is then inserted into a suitable expression vector which when transferred to a suitable host organism, e.g. E. coli, Bacillus or yeast, generates the desired product. The expressed product is then isolated from the cells or the culture broth depending on whether the expressed product is secreted from the cells or not.
The novel insulin analogues may also be prepared by chemical synthesis by methods analogue to the method described by Marki et al. (Hoppe-Seyler's Z. Physiol.Chem., 360 (1979), 1619-1632). They may also be formed from separately in vitro prepared A- and B-chains containing the appropriate amino acid residue substitutions, whereupon the modified A- and B-chains are linked together by establishing disulphide bridges according to known methods (e.g. Chance et al., In: Rick DH, Gross E (eds) Peptides: Synthesis - Structure - Function. Proceedings of the seventh American peptide symposium, Illinois, pp. 721-728).
The insulin analogues may furthermore be prepared by a method analogue to the method described in EP 0163529A, the disclosure of which is incorporated by reference hereinto. By such a method an insulin precursor of human insulin wherein LySB29 is connected to GlyA1 by means of either a peptide bond or a peptide chain of varying length with correctly positioned disulphide bridges is expressed and secreted by yeast and then converted into human insulin by the so-called transpeptidation reaction.
The transpeptidation reaction is described in US patent specification No. 4,343,898 (the disclosure of which is incorporated by reference hereinto). In this reaction the peptide bond or peptide chain connecting LysB29 and GlyA1 is exised and a threonine ester or threonine amide group is coupled to the C-terminal end of LysB29.
The novel insulin analogues may thus be prepared by a method wherein a biosynthetic insulin precursor with the following formula II
wherein Q is a peptide chain with q amino acid residues, q is an interger from 0 to 33, T is Lys or Arg, r is 0 or 1 and X1, X2, X3, X4, X5, X6 and Z are defined as above, is reacted with a compound of the formula III
HY (III) wherein Y is a protected threonine amino acid wherein the carboxyl group is protected with an ester or amido group, using trypsin or trypsin like enzymes as a catalyst in a mixture of water and organic solvent. The ester or amido protecting group may then be cleaved off by acid or basic hydrolysis. Preferred compounds of formula III are Thr-NH2, Lys(Boc)-NH2, Thr(But)-OBut and Thr-OBut.
Insulin preparations of this invention are prepared by dissolving a compound of formula I in an aqueous medium at slightly acidic conditions, for example, in a concentration of 240 or 600 nmole/ml. The aqueous medium is made isotonic, for example, with sodium chloride or glycerol. Furthermore, the aqueous medium may contain zinc ions in a concentraion of up to about 30 μg of Zn++ per nmol of compound of formula I, buffers such as acetate, citrate and histidine and preservatives such as m-cresol, nipagin or phenol . The pH value of the final insulin preparation depends upon the number of charges that have been changed in the compound of formula I, the concentration of zinc ions, the concentration of the compound of formula I and the compound of formula I selected. The pH value is adjusted to a value convenient for administration such as about 2.5 - 5.5, preventing precipitation. The insulin preparation is made sterile by sterile filtration.
The insulin preparations of this invention can be used similarly to the use of the known insulin preparations.
Terminology
The abbreviations used for the amino acids are those stated in J.Biol.Chem. 243 (1968), 3558. The amino acids are in the L configuration. Unless otherwise indicated, the species of insulins stated herein is human.
As used in the following text B(l-29) means a shortened B-chain of human insulin from PheB1 to LysB29 and A(1-21) means the A-chain of human insulin.
The substitution (s) made in the huamn insulin molecule according to the practice of the invention is (are) indicated with a prefix referenced to human insulin. As an example ArgB2 human insulin means a human insulin analogue wherein Arg has been substituted for Val in position 2 in the B-chain. ArgB2, B ( 1-29 )-Ala-Ala-Lys-A(1-21) human insulin means a precursor for the forementioned insulin analogue wherein Arg has been substituted for Val in position 2 in the shortened B-chain and wherein the B(1-29) chain and the A(1- 21) chain are connected by the peptide sequence Ala-Ala-Lys.
Unless otherwise stated it is to be understood that the B(l-29) chain and the A(1-21) chain are connected by disulphide bridges between CysA7 and CysB7 and between CysA20 and CysB19, respectively, and that the A-chain contains an internal disulphide bridge between CysA6 and CysA1, as in human insulin.
Experimental part
Example 1
ArgB2,ProB3,SerA21,ThrB30-NH2 human insulin,
ArgB5,SerA21,ThrB30-NH2 human insulin,
ArgB4,GlyA21,ThrB30-NH2 human insulin and
ArgB2 , ProB3 ,GlyA21,ThrB30 human insulin
ArgB3,GlyA21,ThrB30-NH2 human insulin The above compounds were synthesized from the corresponding the following precursors:
ArgB2,ProB3,SerA21,B(l-29)-Ala-Ala-Lys-A(1-21) human insulin, ArgB5,SerA21,B(l-29)-Ala-Ala-Lys-A(1-21) human insulin, ArgB4,GlyA21,B(l-29)-Ala-Ala-Lys-A(1-21) human insulin, ArgB2,ProB3,GlyA21,B(l-29)-Ala-Ala-Lys-A(1-21) human insulin, and
ArgB3,GluA21,B(l-29)-Ala-Ala-Lys-A(1-21) human insulin by tryptic transpeptidation in organic/aqueous solution in the presence of Thr-NH2 as described in EP 0194864A, Examples 4 and 6. Yields, charges relative to human insulin, rates of migration relative to insulin in DISC PAGE electrophoresis at pH 8.9 and deviations in amino acid compositions from human insulin appear from Table I. The insulin precursors were produced by a method analogous to the method described in EP 0163529A.
The insulin precursors were recovered from the fermentation broths by adsorption of LiChroprep™ RP-18 as described in Example 7 of EP 0163529A. The precursors were eluted from the column with 0.2 M KCl, 0.001 M HCl in 33% (v/v) ethanol. The insulin precursors were crystallized from the pool by successive additions of water (1 volume per volume of pool), solid trisodium citrate to obtain a molarity of 0.05 M and finally zinc acetate to obtain a molarity of 0.006 M. The pH value was adjusted to 6.8 and the mixture was left overnight at 4°C. The crystals were isolated by centrifugation, washed with water and dried in vacuo.
Protected amino acids and protected peptides for enzymatic semisynthesis were either prepared by standard methods or purchased (custom synthesis) from either Nov Biochem or Bachem, both Switzerland.
Table I
Substitution in Yield Charge relative Rate of migration Deviations in amino human insulin % to human at pH 8.9, acid compositions
insulin at pH 7 % relative to from human insulin
human insulin after acid hydrolysis
residues/mole
ArgB2,ProB3,SerA21, 27 +2 55 +1 Arg, +1 Pro, +1 Ser, ThrB30_NH2 -2 Asp, -1 Val
ArgB5,SerA21, 54 +2 55 +1 Arg, +1 Ser,
ThrB30-NH2 -1 Asp, -1 His
ArgB4,GlyA21, 48 +2 55 +1 Arg, +1 Gly,
ThrB30,NH2 -1 Glu, -1 Asp
ArgB2, ProB3, GlyA21, 57 +2 55 +1 Arg, +1 Pro, +1 Gly, ThrB30-NH2 -1 Val, -2 Asp
Sterile injectable solutions of the above compounds for testing of the degree of prolonged action were made using 1.6% (w/v) glycerol as the isotonicum, and 0.26% (w/v) phenol as the preservative. The concentration of zinc ions was 8, 80 or 160 μg/ml. The pH values of the solutions were adjusted sufficiently off the isoelectric point of the analogues to keep the solutions clear upon storage at 4°C. The solutions contained 240 nmole/ml of the tested compounds. The concentration of 240 nmole/ml was verified by HPLC.
Injectable solutions containing 240 nmole/ml of the compounds stated in Table II and having the pH of 3 and content of zinc stated therein were then made.
The prolongation of the hypoglycemic effect was tested according to British Pharmacopoeia 1980, A 142, in fasted rabbits. Each test solution was administered subcutaneously in a dosis of 14.3 nmole per rabbit in 12 animals weighing 3 - 4 kg, and the course of the hypoglycemia was followed for 6 hours. For comparison the fast acting preparation, Actrapid™ human insulin was included in the tests. The results of the tests are shown in Table II giving the percentage of glucose after 1, 2, 4 and 6 hours (h) . Results from determination of biological potencies Mouse Blood Glucose Assay (MBG) and Free Fat Cell Test (FFC) are listed in Table III.
Table II
Compound Zn ++ Glucose in percent of initial
Substitutions in human insulin μg/ml 1h 2h 4h 6h
ArgB5, SerA21, ThrB30-NH2 8 59 64 96 94
ArgB5,Ser 21,ThrB30-NH2 80 85 92 97 95
ArgB5, SerA21 ,ThrB30-NH2 160 76 89 96 94 ArgB2,ProB3, SerA21 ,ThrB30-NH2 8 58 67 73 72
ArgB2,ProB3,SerA21,ThrB30-NH2 80 73 66 64 61 Actrapid™ human insulin 7 53 53 92 97
Table III
Biological potency relative to human insulin.
(British Pharmacopoeia 1980, A141 - A142).
MBGA FFC
Potency Potency
relative Confidence relative to Confidence
Substitutions in to human limits, % human limits, % human insulin insulin, % (P = 0.05) insulin, % (p = 0.05)
ArgB5 , SerA21,ThrB30-NH2 76 86-68 56 54-58
ArgB2 proB3, SerA21,
ThrB30-NH2 56 49-64 50 47-52
ArgB2. ProB3 ,GlyA21,
ThrB30-NH2 59 57-61
ArgB4 , GlyA21 ,ThrB30-NH2 66 60-72 40 38-41

Claims

1. Human insulin analogues having the following formula I
wherein Z is Asn or another naturally occuring amino acid residue, X1 is Phe, Lys or Arg, X2 is Val, Pro, Lys or Arg, X3 is Asn, Lys, Arg or Pro, X4 is Gin, Lys, Arg or Pro, X5 is His, Lys, Arg or Pro, X6 is Lys, Arg, Leu or Pro and Y is a threonine residue wherein the carboxyl group may be blocked by an ester or amido group, with the proviso that at least one of X1 , X2, X3, X4, X5 and X6 is Lys or Arg.
2. Human insulin analogues according to claim 1, wherein X1 is Phe.
3. Human insulin analogues according to claim 1 or 2 wherein Z is Gly, Ala or Ser.
4. Human insulin analogues according to claim 1 wherein X1 is Phe, X2 is Arg or Lys, X3 is Pro, X4 is Gin, X5 is His, X6 is Leu, Z is Gly, Ala or Ser and Y is Thr-NH2 or Thr.
5. Human insulin analogues according to claim 1 wherein X1 is Phe, X2 is Val, X3 is Asn, X4 is Gin, X5 is
His, X6 is Arg or Lys, Z is Gly, Ala or Ser and Y is Thr-NH2 or Thr.
6. Injectable solutions with prolonged insulin action containing a human insulin analogue with the general formula I
wherein Z is Asn or another naturally occuring amino acid, X1 is Phe, Lys or Arg, X2 is Val, Lys or Arg, X3 is Asn, Lys, Arg or Pro, X4 is Gin, Lys, Arg or Pro, X5 is His, Lys, Arg or Pro, X6 is Lys, Arg, Leu or Pro and Y is a threonine residue wherein the carboxyl group may be blocked by an ester or amido group, with the proviso that at least one of X1, X2, X3, X4, X5 and X6 is Lys or Arg, together with conventional auxiliary agents, such as buffers, preservatives and agents making the solution isotonic.
7. A method for making insulin analogues with the following formula I
wherein Z is Asn or another naturally occuring amino acid residue, X1 is Phe, Lys or Arg, X2 is Val, Pro, Lys or Arg, X3 is Asn, Lys, Arg or Pro, X4 is Gin, Lys, Arg or Pro, X5 is His, Lys, Arg or Pro, X6 is Lys, Arg, Leu or Pro and Y is a threonine residue wherein the carboxyl group may be blocked by an ester or amido group, with the proviso that at least one of X1 , X2, X3 , X4, X5 and X6 is Lys or Arg, wherein an insulin percursor with the following formula II
wherein Q is a peptide chain with q amino acid residues, q is an interger from 0 to 33, T is Lys or Arg, r is 0 or 1 and X1, X2, X3, X4, X5, X6 and Z are defined as above, is reacted with a compound of the formula III
HY (HI) wherein Y is a protected threonine amino acid residue wherein the carboxyl group is protected with an ester or amido group, using trypsin or trypsin like enzymes as a catalyst in a mixture of water and organic solvent, whereupon the protecting group if desired is cleaved off by acid or basic hydrolysis.
EP91912264A 1990-06-28 1991-06-21 Novel, protracted insulin analogues Withdrawn EP0536245A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK155690A DK155690D0 (en) 1990-06-28 1990-06-28 NEW PEPTIDES
DK1556/90 1990-06-28

Publications (1)

Publication Number Publication Date
EP0536245A1 true EP0536245A1 (en) 1993-04-14

Family

ID=8106031

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91912264A Withdrawn EP0536245A1 (en) 1990-06-28 1991-06-21 Novel, protracted insulin analogues

Country Status (10)

Country Link
EP (1) EP0536245A1 (en)
JP (1) JPH05508406A (en)
AU (1) AU8054391A (en)
DK (1) DK155690D0 (en)
IE (1) IE912247A1 (en)
IL (1) IL98596A0 (en)
NZ (1) NZ238718A (en)
PT (1) PT98124A (en)
WO (1) WO1992000321A1 (en)
ZA (1) ZA914830B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
CA2215694A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE19726167B4 (en) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
DE10227232A1 (en) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
EP1708755B1 (en) 2004-01-21 2012-03-21 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
CN101573133B (en) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 PEGylated, extended insulins
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
RU2524423C2 (en) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Novel insulin derivatives with extremely delayed time/action profile
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2650621T3 (en) 2008-10-17 2018-01-19 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
DE102008064270A1 (en) * 2008-12-20 2010-07-01 Voith Patent Gmbh Flotation method for removing contaminants from aqueous fibrous material suspension by gas bubbles, involves supplying stream of fibrous material suspension along interference body after supplying stream of gas
CN107080836A (en) 2009-07-06 2017-08-22 赛诺菲-安万特德国有限公司 Aqueous insulin preparation containing methionine
JP2012532177A (en) * 2009-07-06 2012-12-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Thermal and vibration stable insulin formulations
WO2011003823A1 (en) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
MX2012001399A (en) 2009-07-31 2012-03-21 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate.
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
TWI468171B (en) 2009-11-13 2015-01-11 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
PE20121362A1 (en) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING DESPRO36EXENDIN-4 (1-39) -LYS6-NH2, INSULIN GLY (A21) -ARG (B31) -ARG (B32) AND METHIONINE
EP2585484A1 (en) * 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
CN102933599A (en) 2010-06-23 2013-02-13 诺沃—诺迪斯克有限公司 Human insulin containing additional disulfide bonds
WO2011161125A1 (en) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
RU2546520C2 (en) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Application of ave0010 for production of medication for treatment of type 2 diabetes mellitus
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
WO2012123519A2 (en) * 2011-03-15 2012-09-20 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (en) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104364260B (en) 2012-04-11 2017-02-22 诺和诺德股份有限公司 insulin formulations
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en) 2012-06-04 2017-05-22 Diamedica Inc Kallikrein-1-glycosylation isoforms of human tissue
US9707275B2 (en) 2012-12-19 2017-07-18 Wockhardt Limited Stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (en) 2012-12-26 2016-02-25 ウォックハート リミテッド Pharmaceutical composition
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN105579052A (en) 2013-09-30 2016-05-11 沃克哈特有限公司 Pharmaceutical composition
JP6499184B2 (en) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス Novel derivatives of insulin analogues
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
MX2016008978A (en) 2014-01-09 2016-10-04 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives.
RU2016132342A (en) 2014-01-09 2018-02-14 Санофи STABILIZED PHARMACEUTICAL COMPOSITIONS BASED ON INSULIN ANALOGUES AND / OR INSULIN DERIVATIVES
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
RS64300B1 (en) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
TWI700092B (en) 2016-12-16 2020-08-01 丹麥商諾佛．儂迪克股份有限公司 Insulin containing pharmaceutical compositions
CN110446501A (en) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 The dosage form of tissue kallikrein 1
AU2018317810A1 (en) 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
CN109646396A (en) * 2018-12-29 2019-04-19 江苏万邦医药科技有限公司 A kind of stable insulin analog injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (en) * 1975-08-13 1977-02-24 Hoechst Ag Prolonged action insulin analogues - with A1-glycine replaced by D-alanine or D-serine
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (en) * 1988-05-11 1988-05-11 Novo Industri As NEW PEPTIDES
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9200321A1 *

Also Published As

Publication number Publication date
NZ238718A (en) 1992-06-25
PT98124A (en) 1992-04-30
DK155690D0 (en) 1990-06-28
IL98596A0 (en) 1992-07-15
JPH05508406A (en) 1993-11-25
IE912247A1 (en) 1992-01-01
WO1992000321A1 (en) 1992-01-09
ZA914830B (en) 1992-03-25
AU8054391A (en) 1992-01-23

Similar Documents

Publication Publication Date Title
EP0536245A1 (en) Novel, protracted insulin analogues
EP0254516B1 (en) Novel Peptides
EP0194864B1 (en) Novel peptides
US5008241A (en) Novel insulin peptides
US4946828A (en) Novel insulin peptides
AU612141B2 (en) Novel insulin derivatives
JP3129722B2 (en) New insulin derivative
US6451970B1 (en) Peptide derivatives
US7229964B2 (en) Insulin derivatives
US4701440A (en) Insulin derivatives, processes for their preparation and their use, and pharmaceutical agents for the treatment of diabetes mellitus
FI79786C (en) Process for the preparation of a pharmaceutical agent for the treatment of diabetes
EP0678522B1 (en) Insulin analogs
US20060030518A1 (en) Acylated insulin
US20020160938A1 (en) Covalently bridged insulin dimers
KR19980703039A (en) Insulin derivatives
Markussen et al. Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain
JPH0691834B2 (en) Method for producing insulin derivative
EP2720711A1 (en) Multi substituted insulins
JP3131215B2 (en) New insulin derivative
US20040242460A1 (en) Stabilized acylated insulin formulations
NAITHANI et al. Semisynthesis of human proinsulin, I. Preparation of arginyl-A-chain cyclic bis-disulfide
KR920005659B1 (en) Process for preparing insulin derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930621

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940103